S U M M A R Y Twelve spastic patients received single oral doses of a new anti-spastic drug DS103-282 (Sandoz) 6 mg, baclofen 20 mg, and placebo on three separate days. Passive stretch responses were measured before administration and for four hours afterwards. DS103-282 was more effective than baclofen, and both drugs were more effective than placebo. Analysis of the recordings confirmed that DS103-282 had a specific effect upon stretch reflexes independent of its effect on resting muscle tone. Its action appeared at 30 to 45 minutes after ingestion, with maximum activity at 60-90 minutes. Unwanted effects of DS103-282 were drowsiness and (in one case) potentiation of antihypertensive therapy.
DS103-282 (Sandoz) is a centrally acting benzothiadiazol derivative (5-chloro-4 [2-imidazole-2-ylamino] -2, 1, 3-benzothiadiazole), which in preliminary clinical trials has been shown to reduce muscle tone in mean daily oral doses of 4-9 mg.1 2 We present an analysis of its effect upon slow stretch responses in 12 spastic patients.
Method
Subjects studied Twelve adult voluniteers were studied. Their clinical details are summarised in table 1. Pregnant women and patients with heart disease were excluded from the study. Preparation of subjects Antispastic medication was discontinued for three days before the study in the three patients who were routinely taking it. They had a light lunch, consisting of a salad and fruit juice and after control measurements an oral dose of 6 mg DS103-282, 20 mg baclofen or matching placebo capsule was given. The patient then sat in a comfortable dental chair for the next 3-or 4 h and assessments were made 30, 45 and 60 min after ingestion and thereafter at 30 min intervals. The laboratory was quiet and the assessment, using a coiled-spring sphygmanome'ter. Measurement The EMG signals were fed also into electronic integrators that could be re-set according to the phase of the potentiometer cycle (this system has been described previously by McLellan et al.3 This enabled the EMG to be integrated cycle by cycle and displayed as a series of spikes by a pen recorder, the height of the spike indicating the amount of EMG activity collected in each epoch. Stretching and shortening phases of this cycle were analysed separately. The effects of the drugs upon activity evoked by stretch could thus be compared with their effects upon the activity occurring during passive shortening of the muscle. Finally, the signals were full-wave rectified and then averaged with a Datalab DL4000 digital averager using the potentiometer signal to trigger the averager at the same point in each cycle. In this way a profile of the EMG activity during the cycle could be established and the position of the peak response in relation to the stretching cycle could be identified.
Results

Integrated EMG scores
The amounts of integrated EMG recorded during passive stretching and shortening phases showed considerable inter-individual variation. Thus, if means and standard deviations were calculated for each set of recordings across the whole patient group, no significant trends could be discerned. Initially, the integrated EMG scores for the stretching phase (corrected for the EMG recording gain) and then for the shortening phase were plotted against time for each set of observations. Lengthening activity and shortening activity was analysed for flexor and extensor muscles. For example, a patient whose quadriceps and hamstring muscle had been analysed at the three repetition rates (0-26, 0 52 and 0-78 Hz) generated 12 curven for each afternoon's recordings (six for each muscle), making 36 curves in all. Before any code was broken, the three sets from the three separate days were ranked by us independently as showing the most, next best and least evidence of an antispastic drug effect.
The results are given in tables 1 and 2. When the scores of the two assessors were averaged, DS103-282 was the most effective antispastic agent in eight cases, baclofen in three cases and placebo in one case.
DS103-282 had similar effects upon extensor and flexor muscles. Each observer ranked the drugs in the same order, but NH favoured DS103-282 more highly than DLMcL, especially in extensor muscles. In discussion after this analysis was com- Table 2 Comparative efficacy of DS103-282, baclofen and placebo in 1I patients. Each figure is the mean number of patients (ranked by the two observers after visual inspection of the records) responding to the various treatments indicated in the left-hand column. Patient 7 had a shortening reaction and only his stretching data are included; data from patient 10, whose recording was terminated when he reacted adversely to DS103-282 are omitted. Stretch responses were suppressed more effectively by DS103-282 than by baclofen in the doses used. In contrast, the suppressive effect of baclofen upon EMG activity during muscle shortening was similar to the effect of DS103-282. figure (A and B) , indicating that both drugs were relatively more effective in the extensor than flexor muscles. Ind!ividual data from placebo and treatment sessions were then compared, statistical analysis using the Student's paired t test giving the results shown in table 3. The effect of DS103-282 effects than baclofen or placebo, the commonest effect being drowsiness. From the patients' commentts it appears that this drowsiness came on later than the peak anti-spastic effect and may therefore be due to an active metabolite. No patient received concurrent medication except one patient at his third day of aittendance. Following our second day of assessment he had visited his general practitioner, who had found his blood pressure to be raised and prescribed methyldopa 250 mg twice daily. The patient forgot to inform us of this and became hypotensive after receiving 
